Table: Daiichi Sankyo -2025/26 parent results
To Cancel 31,457,200 Shares, 1.73% Of Issued Shares
Occurrence Of Losses Related To Review Of Product Supply Plans
Table: Daiichi Sankyo -2025/26 group forecast(IFRS)
Japan's Nikkei roars past 62,000 on earnings, Middle East optimism; JGBs rally (updated)
Japan's Nikkei surges past 61,000 for first time on earnings, Mideast optimism
Daiichi Sankyo Announces Rescheduling Of Announcement Of Consolidated Financial Results For Year Ended March 31, 2026
By Welcoming Daiichi Sankyo Healthcare To Suntory Group, Expect To Expand Business Across Self-Care And Self-Medication Domains
To Transfer Daiichi Sankyo Healthcare Stock To Suntory Holdings
Brief: Suntory Holdings To Buy Daiichi Sankyo Healthcare For About 200 Billion Yen, Nikkei Says
Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy
Brief: Nuvation Bio Announces Acquisition Of Japan Rights To Safusidenib From Daiichi Sankyo
Nuvation Bio rises after securing Japan rights to brain cancer drug
Brief: Tempus Announces Strategic Collaboration With Daiichi Sankyo To Advance Ai-Driven Biomarker Discovery And Clinical Differentiation Across An Adc Clinical Program
Tempus AI rises after partnering with Daiichi Sankyo for cancer drug
Brief: Leveragen Collaboration With Daiichi Sankyo To Support Development Of Advanced Biologics Using Next-Gen In Vivo Antibody Discovery Platforms
Brief: Daiichi Sankyo Says ENHERTU Gets U.S. Priority Review For HER2‑Positive Early Breast Cancer
Brief: Sylamorebio Announces Research Collaboration With Daiichi Sankyo
Brief: IHH Healthcare Says On Feb 12 NTK Submitted Petition To Further Amend NTK’s Claim Against Daiichi Sankyo